CPT® Code 81540

1. Indications

The CPT® Code 81540 is indicated for use in the evaluation of tumors of unknown origin, particularly in cases where carcinoma of unknown primary site (CUP) is suspected. The following conditions and scenarios may warrant the use of this molecular genetic testing:

• Carcinoma of Unknown Primary Site (CUP) This test is specifically designed for patients presenting with tumors that do not have a clearly identifiable primary site, which complicates diagnosis and treatment planning.
• Aggressive Tumors Tumors that are diagnosed in multiple locations at the same time are often aggressive and require precise classification to guide treatment options.
• Diagnostic Uncertainty In cases where traditional diagnostic methods, such as immunohistochemical staining, yield inconclusive results, this genetic profiling can provide additional clarity.

2. Procedure

The procedure for CPT® Code 81540 involves several critical steps to ensure accurate gene expression profiling. The following outlines the detailed procedural steps:

• Step 1: Sample Preparation The process begins with the collection of formalin-fixed paraffin-embedded tissue samples from the patient. These samples are prepared in a manner that preserves the cellular structure and genetic material for analysis.
• Step 2: RNA Extraction Once the tissue samples are prepared, messenger RNA (mRNA) is extracted from the preserved tissue. This step is crucial as it isolates the genetic material necessary for subsequent analysis.
• Step 3: cDNA Synthesis The extracted mRNA is then converted into complementary DNA (cDNA) using a technique known as real-time reverse transcription polymerase chain reaction (RT-PCR). This conversion is essential for amplifying the genetic material for further testing.
• Step 4: Gene Expression Profiling The cDNA is analyzed for the expression of 92 specific genes, which include 87 content genes and 5 housekeeping genes. This profiling assesses the levels of gene expression that are indicative of various tumor types.
• Step 5: Data Comparison and Probability Scoring The results from the gene expression profiling are compared against a comprehensive database of tumor DNA expression data. This comparison generates a probability score that indicates the likelihood of the patient’s tissue sample correlating with a specific tumor origin and histological subtype.

3. Post-Procedure

After the completion of the gene expression profiling procedure, the results are compiled and reported to the healthcare provider. The probability score generated from the analysis provides critical information that can guide treatment decisions. It is essential for the healthcare team to discuss the findings with the patient, including the implications of the results for potential treatment options. Follow-up care may involve additional diagnostic testing or consultations with oncology specialists to develop a tailored treatment plan based on the identified tumor type and subtype. Continuous monitoring and assessment of the patient's response to treatment may also be necessary to ensure optimal outcomes.